Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Receivables (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Change in Receivables for 9 consecutive years, with -$564000.0 as the latest value for Q2 2022.

  • On a quarterly basis, Change in Receivables fell 158.45% to -$564000.0 in Q2 2022 year-over-year; TTM through Dec 2022 was -$1.6 million, a 8.23% decrease, with the full-year FY2022 number at -$1.6 million, down 8.23% from a year prior.
  • Change in Receivables was -$564000.0 for Q2 2022 at Gyre Therapeutics, up from -$1.1 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.8 million in Q4 2020 to a low of -$13.6 million in Q1 2020.
  • A 3-year average of -$1.5 million and a median of -$498500.0 in 2020 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: surged 83.08% in 2021, then tumbled 158.45% in 2022.
  • Gyre Therapeutics' Change in Receivables stood at $1.8 million in 2020, then tumbled by 59.95% to $704000.0 in 2021, then tumbled by 180.11% to -$564000.0 in 2022.
  • Per Business Quant, the three most recent readings for GYRE's Change in Receivables are -$564000.0 (Q2 2022), -$1.1 million (Q1 2022), and $704000.0 (Q4 2021).